-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BT-595 in Primary Immune Deficiency (PID)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BT-595 in Primary Immune Deficiency (PID) Drug Details:BT-595 is under development for the treatment of primary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BT-595 in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BT-595 in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drug Details:BT-595 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HHSCC-244 in Non-Small Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HHSCC-244 in Non-Small Cell Lung Cancer Drug Details: Glumetinib (HHSCC-224) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Cefepime + Zidebactam) in Pyelonephritis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cefepime + Zidebactam) in Pyelonephritis Drug Details: A fixed dose combination of cefepime and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BT-588 in Community Acquired Pneumonia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BT-588 in Community Acquired Pneumonia Drug Details: BT-588 (IgM concentrate) is under development as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gumarontinib in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Gumarontinib in Non-Small Cell Lung CancerDrug Details:Glumetinib (Haiyitan) is an anti neoplastic agent which inhibit the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Relatlimab in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Relatlimab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Relatlimab (BMS-986016) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tremelimumab in Neuroblastoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tremelimumab in Neuroblastoma Drug Details: Tremelimumab (Imjudo) human monoclonal monospecific antibody against CTLA-4. It is...
-
Company Profile
![]()
Biotest AG – Company Profile
Biotest AG (Biotest), a subsidiary of Grifols SA, provides pharmaceutical and biotherapeutic drugs. It develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products include clotting factors, immunoglobulins, albumin and monoclonal antibodies in clinical development. The company specializes in the areas of clinical immunology, haematology and intensive care medicine. Biotest distributes its products through local marketing partners and distributors in Europe, North America, South America, Asia, the Middle East and...
Add to Basket -
Product Insights
![]()
Respiratory Disease Tests – Hangzhou Biotest Biotech Co., Ltd. – CORONACHEK
GlobalData, the industry analysis specialist, has released its latest report: Respiratory Disease Tests - Hangzhou Biotest Biotech Co., Ltd. - CORONACHEK. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.